結(jié)直腸癌是全球最常見的惡性腫瘤，奧沙利鉑作為新型鉑類抗癌藥的廣泛應(yīng)用顯著提高了結(jié)直腸癌患者的生存率，但化療耐藥性使其療效受限，導(dǎo)致預(yù)后不良。近年來，越來越多的證據(jù)表明長鏈非編碼RNA（lncRNA）在產(chǎn)生藥物抵抗過程中發(fā)揮不可替代的作用，特異性lncRNA可作為結(jié)直腸癌的新型治療靶點(diǎn)和生物標(biāo)志物。歸納總結(jié)了lncRNA參與奧沙利鉑耐藥的調(diào)節(jié)通路，lncRNA的調(diào)控可能為研究新型的結(jié)直腸癌治療藥物提供線索，提高耐藥患者的治療效果，改善臨床療效。

Colorectal cancer is the most common malignant tumor in the world. The widespread application of oxaliplatin as a new type of platinum-based anticancer drug has significantly improved the survival rate of patients with colorectal cancer, but the chemotherapy resistance has greatly reduced the efficacy of the drug and led to poor prognosis. In recent years, more and more evidence has shown that long non-coding RNAs (lncRNAs) play an irreplaceable role in the process of drug resistance, and specific lncrnas can be used as novel therapeutic targets and biomarkers for colorectal cancer. The regulation pathway of lncRNA involved in oxaliplatin resistance was summarized. The regulation of lncRNA may provide clues for the study of novel colorectal cancer treatment drugs, improve the therapeutic effect of drug-resistant patients, and improve the clinical efficacy.

R965.3；R969.4

2022年內(nèi)蒙古醫(yī)科大學(xué)面上項(xiàng)目（YKD2022MS016）